TL;DR
This study investigates the impact of periprocedural myocardial infarction (PMI) after left main coronary artery PCI in patients who recently experienced a heart attack. They found that a significant rise in CK-MB levels (≥10x the upper limit of normal) after the procedure is a strong predictor of long-term mortality, while troponin levels were not. The SCAI definition of PMI showed the strongest association with adverse outcomes, suggesting its utility in identifying high-risk patients.
What Problem Does This Paper Address?
Coronary artery disease affecting the left main coronary artery (LMCAD) is a critical condition, and percutaneous coronary intervention (PCI) is a common treatment. However, for patients who have recently had a myocardial infarction (MI), PCI for LMCAD poses a higher risk. A key concern is "periprocedural myocardial infarction" (PMI) – a new heart muscle injury occurring during or shortly after the PCI procedure. The problem is that there's no universally agreed-upon definition for what constitutes a "clinically relevant" PMI, especially in high-risk patients like those with recent MI. Different definitions use varying biomarkers (CK-MB vs. troponin), different thresholds for elevation, and different criteria for supporting evidence of ischemia. This ambiguity makes it difficult to accurately assess the risk associated with PMI and to compare outcomes across studies. This paper aims to clarify which definitions and biomarker thresholds are most predictive of long-term mortality in this specific, vulnerable patient population.
Methods
The researchers conducted a retrospective analysis of a prospective registry of patients who underwent PCI for LMCAD at Fu Wai Hospital between January 2004 and December 2016. They specifically focused on a subset of 350 patients who had experienced a recent MI (within 30 days) and had elevated cardiac biomarkers (CK-MB or troponin I) that were stable or falling before the PCI. This pre-selection was crucial to avoid confounding from ongoing MI at the time of the procedure.
They then evaluated PMI using three established definitions: the fourth Universal Definition of Myocardial Infarction (UDMI), the Academic Research Consortium-2 (ARC-2), and the Society for Cardiovascular Angiography & Interventions (SCAI) criteria. For each definition, they assessed the frequency of PMI and its association with 3-year rates of cardiovascular (CV) death and all-cause death. Additionally, they explored the prognostic significance of specific biomarker thresholds for both CK-MB and troponin I, both with and without supporting evidence of myocardial ischemia (like ECG changes or imaging abnormalities).
Datasets
The study utilized data from the Fuwai LMCAD PCI registry, a prospective collection of patient information from Fu Wai Hospital. The dataset comprised 350 patients who met specific inclusion criteria (recent MI, elevated and stable/falling pre-PCI biomarkers). No new datasets were introduced.
Key Insights and Ideas
- CK-MB Reigns Supreme (for Prognosis): The study strongly suggests that a significant rise in CK-MB (≥10x the upper reference limit) after PCI is a much more reliable indicator of future adverse events than troponin levels, even very high troponin elevations. This challenges the trend towards universal adoption of high-sensitivity troponin assays without considering their prognostic utility in specific contexts.
- SCAI Definition Offers Strongest Prognostic Signal: Among the established PMI definitions, the SCAI criteria demonstrated the most robust association with 3-year mortality. This implies that the SCAI definition, which often relies on a substantial CK-MB rise, might be better at capturing clinically significant periprocedural injury in this high-risk group.
- The "Big Hitters" Matter Most: When the researchers analyzed the data by removing patients who met the SCAI definition from the ARC-2 and UDMI groups, the remaining smaller PMIs lost their prognostic significance. This suggests that it's the larger, more substantial myocardial injuries that drive adverse outcomes, and the SCAI definition is better at identifying these.
- Ischemia Evidence is Secondary: The presence of ECG changes or angiographic complications didn't significantly alter the prognostic value of biomarker elevations, particularly for CK-MB. This implies that the biomarker rise itself, especially a substantial CK-MB rise, is the primary driver of risk, rather than the accompanying procedural events.
Key Results
- PMI Prevalence: The incidence of PMI varied significantly by definition: 19.4% by fourth UDMI, 12.3% by ARC-2, and 8.6% by SCAI.
- CK-MB Thresholds: An incremental post-PCI CK-MB rise of ≥10x the upper reference limit was significantly associated with a 7.96-fold increased risk of 3-year CV death (adjusted hazard ratio [aHR]) and a 5.43-fold increased risk of all-cause death.
- Troponin Insignificance: No level of troponin I elevation after PCI was associated with a significant risk of 3-year CV or all-cause death.
- Definition Impact: All three PMI definitions were associated with increased 3-year mortality. The SCAI definition showed the strongest association (aHR for CV death: 6.34), followed by ARC-2 (aHR: 2.82) and fourth UDMI (aHR: 2.65).
- Mortality Rates: Patients with PMI by the SCAI definition had a 33.3% 3-year CV death rate, compared to 4.7% in those without PMI.
Limitations and Future Work
The authors acknowledge several limitations:
- Observational Study: As a retrospective analysis of a prospective registry, causality cannot be definitively proven.
- Single Center: Data comes from a high-volume center with experienced operators, which may limit generalizability.
- Outcome Variable: Death was the primary outcome. Future studies should investigate the impact of PMI on left ventricular function, heart failure, and quality of life.
- Sample Size: While the largest study of its kind, the number of PMI events and deaths was modest, potentially limiting the detection of smaller but significant relationships.
- Biomarker Assay: The study used a standard troponin assay. Results might differ with high-sensitivity troponin assays.
- Patient Selection: Patients with unstable biomarkers before PCI were excluded, meaning the findings may not apply to those requiring immediate PCI due to hemodynamic instability.
Future work should focus on validating these findings in larger, multi-center studies and exploring the impact of PMI on a broader range of clinical outcomes. Further research into the optimal biomarker and threshold for defining clinically relevant PMI, especially in the context of evolving troponin assays, is also warranted.
Summary updated